GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Clinical trial NCT00251433 · TERMINATED
Trial details
- NCT number
- NCT00251433
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2005-09-26
- Primary completion
- 2010-06-10
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.